BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Clinical Trials
1.7k
Trial Phases
6 Phases
Drug Approvals
11
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1339 trials with phase data)• Click on a phase to view related trials
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: Current standard of care treatment options
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 223
- Registration Number
- NCT07175285
- Locations
- 🇺🇸
Local Institution - 0035, San Diego, California, United States
🇺🇸Local Institution - 0034, Ann Arbor, Michigan, United States
🇺🇸Local Institution - 0039, Brooklyn, New York, United States
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Placebo
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT07171983
Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 163
- Registration Number
- NCT07168655
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
- Conditions
- Solid Tumours
- Interventions
- Drug: BMS-986517
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 315
- Registration Number
- NCT07160725
- Locations
- 🇺🇸
Local Institution - 0002, Los Angeles, California, United States
🇺🇸Local Institution - 0021, Orange, California, United States
🇺🇸Local Institution - 0008, Pittsburgh, Pennsylvania, United States
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: Nivolumab + platinum-based chemotherapy
- First Posted Date
- 2025-08-26
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT07141563
- Locations
- 🇦🇷
Grupo Argentino Oncología Torácica (GAOT) - Asociación Argentina Oncología Clínica (AAOC), Buenos Aires, Argentina
- Prev
- 1
- 2
- 3
- 4
- 5
- 300
- Next
News
Bristol Myers Squibb's Iberdomide Combination Achieves Primary Endpoint in Phase 3 Multiple Myeloma Trial
Bristol Myers Squibb announced that its Phase 3 EXCALIBER-RRMM study evaluating iberdomide in combination with daratumumab and dexamethasone demonstrated statistically significant improvement in minimal residual disease negativity rates compared to standard therapy in relapsed or refractory multiple myeloma patients.
Bristol Myers Squibb Plans 2026 UK Launch of Breakthrough Schizophrenia Drug Cobenfy at $22,500 Annual Price
Bristol Myers Squibb announced plans to launch its schizophrenia treatment Cobenfy in the UK in 2026, pricing it at $1,850 monthly or $22,500 annually to match its U.S. list price.
FAERS Analysis Reveals Lower Infection Risk with Ide-cel Compared to Other BCMA-Targeted Therapies in Multiple Myeloma
A retrospective analysis of FDA Adverse Event Reporting System (FAERS) data from 2021-2024 found that idecabtagene vicleucel (ide-cel) was associated with significantly lower infection rates compared to other BCMA-directed therapies in multiple myeloma patients.
Alnylam Pharmaceuticals Joins Alliance for Genomic Discovery to Accelerate RNAi Drug Development
Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.
AstraZeneca's Saphnelo Subcutaneous Formulation Meets Primary Endpoint in Phase III Lupus Trial
AstraZeneca's subcutaneous formulation of Saphnelo (anifrolumab) demonstrated statistically significant and clinically meaningful reduction in disease activity compared to placebo in the Phase III TULIP-SC trial for systemic lupus erythematosus.
Biocartis Receives FDA Approval for First Fully Automated Companion Diagnostic Test for Colorectal Cancer
Biocartis has received FDA Premarket Approval for the Idylla™ CDx MSI Test, marking the first fully automated, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients.
CatalYm Strengthens Leadership Team to Advance Visugromab Through Late-Stage Development
CatalYm appointed four experienced executives to accelerate visugromab's progression into late-stage clinical development following promising Phase 2a results.
BioNTech-Bristol Myers Bispecific Antibody Achieves 76.3% Response Rate in Small Cell Lung Cancer Phase II Trial
BioNTech and Bristol Myers Squibb's investigational bispecific antibody pumitamig (BNT327) demonstrated a 76.3% confirmed objective response rate in a Phase II trial for extensive-stage small cell lung cancer.
BioNTech and Bristol Myers Squibb Report Promising Phase 2 Results for Pumitamig in Extensive-Stage Small Cell Lung Cancer
BioNTech and Bristol Myers Squibb presented interim Phase 2 data showing pumitamig plus chemotherapy achieved a 76.3% confirmed objective response rate and 100% disease control rate in extensive-stage small cell lung cancer patients.
CHARM Therapeutics Appoints Dr. Erkut Bahceci as CMO to Lead Next-Generation Menin Inhibitor Development
CHARM Therapeutics has appointed Dr. Erkut Bahceci as Chief Medical Officer following an $80 million Series B financing to advance its next-generation menin inhibitor for acute myeloid leukemia.